Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the immunisation protects vulnerable infants

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”

The pregnancy vaccine functions by activating the mother’s body’s defences to generate protective antibodies, which are then passed to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the moment of birth, exactly when they are most vulnerable to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst noting that protection can still occur even if administered later in the third trimester.

• Nearly 85 per cent coverage when immunised 4 weeks before birth
• Maternal antibodies passed through placenta safeguard newborns from day one
• Coverage possible with 2-week gap before premature birth
• Vaccination during the third trimester still provides significant infant protection

Persuasive evidence from recent research

The efficacy of the pregnancy RSV vaccine has been confirmed through a thorough investigation carried out throughout England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that half-year window, providing strong and reliable evidence of the vaccine’s actual performance. The study’s findings have been validated by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The breadth of this investigation provides healthcare professionals and expectant parents with confidence in the vaccine’s proven efficacy across varied populations and settings.

The results reveal a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV throughout the study period, with the vast majority being infants whose mothers had not received the vaccination. This clear distinction highlights the vaccine’s essential role in protecting against serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the distressing and potentially serious symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.

Methodology and scope of study

The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection levels and hospital admissions. The large sample size and thorough nature of the data gathering ensured that findings were statistically robust and reflective of the wider population, rather than isolated cases or small subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology measured real-world outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine performs when administered across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.

Learning about RSV and the hazards

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to serious, potentially fatal chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.

The infection causes inflammation deep within the lungs and airways, making it perilously hard for infected babies to breathe and feed adequately. Parents often witness their babies struggling visibly, their chests rising whilst they try to pull adequate oxygen into their damaged lungs. Whilst most newborns get better with clinical support, a modest yet notable number die from respiratory syncytial virus complications each year, making prevention through vaccination a critical public health imperative for defending the most vulnerable and youngest members of society.

• RSV triggers lung inflammation, causing serious respiratory problems in infants
• Half of all infants acquire the infection during their first few months alive
• Symptoms vary between mild colds to serious chest infections that threaten life requiring hospitalisation
• More than 20,000 UK babies require serious hospital care for RSV annually
• Few infants succumb to RSV related complications each year in the UK

Uptake rates and expert recommendations

Since the RSV vaccine programme commenced in 2024, health officials have highlighted the importance of pregnant women getting their jab at the ideal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing matters greatly for ensuring newborns benefit from the most robust immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery delivers approximately 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies transferred to their babies via the placenta.

The guidance from public health bodies stays clear: pregnant women should make a priority of vaccination during their final three months, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has reassured expectant mothers that protection is still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach acknowledges the realities of pregnancy and childbirth whilst maintaining strong protection for at-risk infants during their most critical early months when RSV poses the greatest risk of severe infection.

Regional differences in vaccination

Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Some areas have attained greater immunisation rates among eligible pregnant women, whilst others remain focused to boost understanding and access to the jab. These geographical variations reflect variations in healthcare infrastructure, communication strategies, and local engagement efforts, though the national data demonstrates consistently strong protection irrespective of geographical location.

• NHS trusts deploying varied communication campaigns to reach pregnant women
• Regional disparities in immunisation take-up in different parts of England demand focused enhancement
• Community health services modifying schemes to align with community needs and circumstances

Real-world impact and parent viewpoints

The vaccine’s impressive effectiveness delivers real advantages for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the introduction of this safeguarding intervention, the 80% drop in admissions equates to thousands of infants protected against critical disease. Parents no longer face the troubling prospect of seeing their babies struggle for breath or labour to feed, symptoms that mark critical RSV illness. The vaccine has substantially transformed the terrain of neonatal breathing health, providing expectant mothers a preventative option to protect their youngest infants during those vital initial period.

For families like that of Malachi, whose acute RSV infection resulted in devastating brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s promotion of the jab underscores the transformative consequences that vaccine-preventable disease can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story strikes a chord with parents now given protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has offered substantial reassurance to expectant mothers during their final trimester, converting what was once an inevitable seasonal threat into a manageable health risk.